CPA
DNLI icon

Capital Performance Advisors’s Denali Therapeutics DNLI Stock Holding History

Capital Performance Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-63
Closed -$1.83K – 851
2024
Q3 		$1.83K Buy
+63
New +$1.56K ﹤0.01% 1605

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital Performance Advisors's DNLI Position: Q4 2024 in Review

Capital Performance Advisors sold out of Denali Therapeutics (DNLI) in Q4 2024, closing a stake of 63 shares — an estimated $1.83K sold.

Capital Performance Advisors first reported a position in DNLI in Q3 2024 and held it in 1 quarter. The position peaked at $1.83K in Q3 2024. 223 funds tracked by Wall St. Rank hold DNLI as of Q4 2024.

  • Capital Performance Advisors reported no remaining Denali Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 63 Denali Therapeutics shares in Q4 2024, an estimated $1.83K.
  • Capital Performance Advisors first reported a position in Denali Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Denali Therapeutics position peaked at $1.83K in Q3 2024.
  • 223 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.